These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

507 related items for PubMed ID: 16401811

  • 1. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.
    DeWitt EM, Glick HA, Albert DA, Joffe MM, Wolfe F.
    Arch Intern Med; 2006 Jan 09; 166(1):57-63. PubMed ID: 16401811
    [Abstract] [Full Text] [Related]

  • 2. Etanercept or infliximab: the patient's considerations.
    Sherrick RC.
    Arch Intern Med; 2006 Jul 10; 166(13):1418; author reply 1418. PubMed ID: 16832010
    [No Abstract] [Full Text] [Related]

  • 3. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA, Klingman D, Hazard E, Ray S.
    Clin Ther; 2009 Apr 10; 31(4):825-35. PubMed ID: 19446156
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population.
    Ollendorf DA, Peterson AN, Doyle J, Huse DM.
    Am J Manag Care; 2002 May 10; 8(7 Suppl):S203-13. PubMed ID: 12022236
    [Abstract] [Full Text] [Related]

  • 6. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis.
    Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M.
    Curr Med Res Opin; 2008 Aug 10; 24(8):2229-40. PubMed ID: 18577308
    [Abstract] [Full Text] [Related]

  • 7. Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first-line therapy.
    Erkan D, Yazici Y, Harrison MJ, Paget SA.
    Arthritis Rheum; 2002 Jun 15; 47(3):285-90. PubMed ID: 12115159
    [Abstract] [Full Text] [Related]

  • 8. Assessing the value of rheumatoid arthritis treatment alternatives: the potential effect of tumor necrosis factor inhibitors.
    Mizutani W.
    Manag Care Interface; 2003 Mar 15; 16(3):44-50, 55. PubMed ID: 12715413
    [Abstract] [Full Text] [Related]

  • 9. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT, Changolkar AK, Scott McKenzie R.
    J Med Econ; 2012 Mar 15; 15(2):332-9. PubMed ID: 22168788
    [Abstract] [Full Text] [Related]

  • 10. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.
    Jonsdottir T, Forslid J, van Vollenhoven A, Harju A, Brannemark S, Klareskog L, van Vollenhoven RF.
    Ann Rheum Dis; 2004 Sep 15; 63(9):1075-8. PubMed ID: 15066863
    [Abstract] [Full Text] [Related]

  • 11. Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis.
    De Filippis L, Caliri A, Anghelone S, Scibilia G, Lo Gullo R, Bagnato G.
    Panminerva Med; 2006 Jun 15; 48(2):129-35. PubMed ID: 16953150
    [Abstract] [Full Text] [Related]

  • 12. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.
    Iannone F, Trotta F, Montecucco C, Giacomelli R, Galeazzi M, Matucci-Cerinic M, Ferri C, Cutolo M, Maria Bambara L, Triolo G, Ferraccioli G, Valentini G, Lapadula G, GISEA (Gruppo Italiano per lo Studio delle Early Arthritis).
    Ann Rheum Dis; 2007 Feb 15; 66(2):249-52. PubMed ID: 16837489
    [Abstract] [Full Text] [Related]

  • 13. [Clinical experience with TNF-alpha inhibitors in rheumatoid arthritis].
    Wallenius M, Rødevand E, Skomsvoll JF.
    Tidsskr Nor Laegeforen; 2005 Jun 16; 125(12):1664-6. PubMed ID: 15976836
    [Abstract] [Full Text] [Related]

  • 14. Effective coverage and reimbursement strategies for etanercept and infliximab in the treatment of rheumatoid arthritis.
    Sokol MC.
    Manag Care Interface; 2005 Apr 16; 18(4):32-7. PubMed ID: 15889761
    [Abstract] [Full Text] [Related]

  • 15. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis.
    Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon RM, Wolfe F.
    Arthritis Rheum; 2008 Apr 16; 58(4):939-46. PubMed ID: 18383356
    [Abstract] [Full Text] [Related]

  • 16. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A.
    Isr Med Assoc J; 2008 Apr 16; 10(4):277-81. PubMed ID: 18548981
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.
    Kastbom A, Bratt J, Ernestam S, Lampa J, Padyukov L, Söderkvist P, Skogh T.
    Arthritis Rheum; 2007 Feb 16; 56(2):448-52. PubMed ID: 17265480
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Etanercept and infliximab for rheumatoid arthritis.
    Drug Ther Bull; 2001 Jul 16; 39(7):49-52. PubMed ID: 11471515
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.